Moderna (MRNA) Stock Slips Despite Beating Q4 Revenue and Earnings Estimates

TLDR Moderna reported Q4 revenue of $678 million, beating Wall Street estimates of $626.1 million, driven by COVID-19 vaccine sales The company posted a quarterly loss of $2.11 per share, narrower than the $2.54 per share loss analysts expected Moderna reiterated its 2026 revenue growth target of 10% and expects 50% of sales from U.S. [...]

The post Moderna (MRNA) Stock Slips Despite Beating Q4 Revenue and Earnings Estimates appeared first on Blockonomi.